# Diabetes Research Hub — Monitor Report
**Date:** 2026-03-15
**Run type:** Scheduled daily scan (baseline)
**Data freshness:** All files generated today

---

## File System Status

All expected files are present and current (generated 2026-03-15):

| File | Size | Last Modified | Status |
|------|------|---------------|--------|
| hub_monitor_report.md | 1.7 KB | 2026-03-15 00:37 | Current |
| hub_monitor_state.json | 3.6 KB | 2026-03-15 00:37 | Current |
| clinical_trials_latest.json | 526 KB | 2026-03-15 00:45 | Current |
| clinical_trials_snapshot_2026-03-15.json | 526 KB | 2026-03-15 00:45 | Current |
| clinical_trials_summary.md | 1.7 KB | 2026-03-15 00:45 | Current |
| literature_gap_data.json | 132 KB | 2026-03-15 00:45 | Current |
| literature_gap_matrix.xlsx | 33 KB | 2026-03-15 00:45 | Current |
| literature_gap_report.md | 4.3 KB | 2026-03-15 00:45 | Current |
| pubmed_recent_latest.json | 96 KB | 2026-03-15 00:46 | Current |
| pubmed_recent_snapshot_2026-03-15.json | 96 KB | 2026-03-15 00:46 | Current |
| pubmed_recent_summary.md | 25.8 KB | 2026-03-15 00:46 | Current |

**Missing/stale files:** None. All scripts have been run and all outputs are fresh.

**Hub monitor notes:** 15 total files tracked. 11 new files detected since previous scan (scripts, gap analysis outputs, dashboard). 7 removed files noted (path format changes from forward-slash to backslash — likely an OS normalization, not actual data loss).

---

## Clinical Trial Changes

### Snapshot Comparison
This is the **baseline run** — today's snapshot is the first on record. No prior snapshot exists for delta comparison. Future runs will compare against today's snapshot.

### Overview (746 Unique Trials)

| Category | Count |
|----------|-------|
| T1D Cure & Cell Therapy | 154 |
| T1D Immunotherapy & Prevention | 71 |
| T2D Novel Therapies (Phase 2-3) | 133 |
| Diabetes Technology (Devices) | 217 |
| Diabetes Recently Completed with Results | 244 |

| Status | Count |
|--------|-------|
| RECRUITING | 254 |
| COMPLETED | 244 |
| NOT_YET_RECRUITING | 133 |
| ACTIVE_NOT_RECRUITING | 108 |

### High-Priority: Phase 3 Recruiting Trials (42 total)

Key Phase 3 recruiting trials to watch:

| NCT ID | Title | Sponsor | Notes |
|--------|-------|---------|-------|
| NCT06832410 | VX-880 in T1D with Kidney Transplant | **Vertex** | Stem cell-derived islets; Phase 3 |
| NCT04786262 | VX-880 in T1D | **Vertex** | Original VX-880 Phase 3 |
| NCT07222137 | Baricitinib to Delay Stage 3 T1D (Adults) | **Eli Lilly** | JAK inhibitor for T1D prevention |
| NCT07222332 | Baricitinib to Preserve Beta Cells (Children) | **Eli Lilly** | Pediatric T1D prevention |
| NCT07076199 | Insulin Icodec (Weekly Insulin) | **Novo Nordisk** | Once-weekly insulin |
| NCT06993792 | Orforglipron Master Protocol | **Eli Lilly** | Oral GLP-1; obesity/overweight |
| NCT07271251 | Oral Semaglutide Formulation Comparison | **Novo Nordisk** | Bioequivalence study |
| NCT07088068 | Teplizumab in T1D | **Sanofi** | Disease-modifying therapy |
| NCT05819138 | Semaglutide CV Outcomes in T1D | U of Colorado | Cardiovascular outcomes |
| NCT06951074 | Insulin Producing Stem Cell Transplant | Ain Shams U | Stem cell therapy |

### Key Organization Trial Summary (53 trials total)

| Organization | Total Trials | Recruiting | Phase 3 |
|--------------|-------------|------------|---------|
| **Eli Lilly** | 27 | Multiple | Baricitinib (x2), Orforglipron, Retatrutide (x2), Tirzepatide, Dulaglutide, Insulin Efsitora |
| **Novo Nordisk** | 23 | Multiple | Insulin Icodec, CagriSema (x3), Oral Semaglutide |
| **Vertex** | 3 | 2 | VX-880 (x2); VX-264 Phase 1/2 active |

### Recently Posted Results
245 trials have posted results. These are primarily from the "Diabetes Recently Completed with Results" category. Notable completed trials with results include islet transplantation studies and CGM validation studies.

---

## PubMed Highlights

### Publication Volume (Last 30 Days, 122 Unique Papers)

**HIGH ACTIVITY domains (most publications):**

| Domain | Papers (30d) | Signal |
|--------|-------------|--------|
| Diabetes AI/ML | 174 | Highest volume — AI in diabetes is surging |
| T2D GLP-1 New | 149 | Strong — driven by orforglipron/CagriSema interest |
| Diabetes Microbiome | 137 | Strong ongoing activity |
| Diabetes Biomarker | 125 | Active discovery phase |
| Diabetes Health Equity | 58 | Notable volume for equity research |
| T2D Remission | 52 | Growing area |

**LOW ACTIVITY domains (may need attention):**

| Domain | Papers (30d) | Signal |
|--------|-------------|--------|
| Diabetes Drug Repurpose | 3 | Very low — aligns with gap analysis (Tier 1 priority area) |
| Diabetes Epigenetics | 2 | Extremely low — potential opportunity |
| LADA New Research | 8 | Low but expected for this niche |

### Cross-Domain Papers (Highest Priority for Review)

10 papers appeared across multiple alert domains — these represent synthesis opportunities:

1. **"Multi-omics analysis of dynamic profiles in response to various nutrient loads provides novel insights into obesity."** — Spans: Biomarker + Microbiome + Multi-Omics. [PMID: 41825203](https://pubmed.ncbi.nlm.nih.gov/41825203/) — *Aligns with Tier 1: Multi-Omics Biomarker Integration*

2. **"Modulating immune response for the prevention and treatment of type 1 diabetes."** — Spans: T1D Stem Cell + Immunotherapy. [PMID: 41777899](https://pubmed.ncbi.nlm.nih.gov/41777899/)

3. **"From survival to freedom: redefining success in type 1 diabetes."** — Spans: T1D Stem Cell + Closed Loop AP. [PMID: 41763233](https://pubmed.ncbi.nlm.nih.gov/41763233/)

4. **"The New Wave of Gene and Cell Therapies Across Diseases."** — Spans: Immunotherapy + Gene Therapy. [PMID: 41827217](https://pubmed.ncbi.nlm.nih.gov/41827217/)

5. **"Hypothesis: Nutrient Off-Loading and Ectopic Fat Reduction Reverse Insulin Resistance."** — Spans: GLP-1 + Remission. [PMID: 41828377](https://pubmed.ncbi.nlm.nih.gov/41828377/)

6. **"MORF4L1 regulation and its role in chromatin remodeling."** — Spans: Remission + Epigenetics. [PMID: 41819434](https://pubmed.ncbi.nlm.nih.gov/41819434/)

7. **"Identification of Retinal Diseases Using Light CNNs."** — Spans: AI/ML + Complications. [PMID: 41828049](https://pubmed.ncbi.nlm.nih.gov/41828049/) — *Aligns with Tier 1: AI/ML Prediction*

8. **"Gut Microbiota-Derived EPA Alleviates Kidney Fibrosis in Diabetic Nephropathy."** — Spans: Microbiome + Multi-Omics. [PMID: 41819520](https://pubmed.ncbi.nlm.nih.gov/41819520/)

9. **"MAPK14/SLC7A11/GPX4 axis drives podocyte ferroptosis."** — Spans: Complications + Multi-Omics. [PMID: 41813669](https://pubmed.ncbi.nlm.nih.gov/41813669/)

10. **"Traditional Foods, Oral Microbiome, and Systemic Health."** — Spans: Microbiome + Multi-Omics. [PMID: 41828628](https://pubmed.ncbi.nlm.nih.gov/41828628/)

### Key Therapy Mentions in Recent Papers

| Therapy | Found? | Details |
|---------|--------|---------|
| **Teplizumab** | Yes | PMID 41796109 — "Teplizumab in Stage 2 T1D: Clinical Practice Experience" (3 adult patients). Domain: T1D Immunotherapy. Evidence level: 3 (case series). |
| Zimislecel | No | No new papers in 30-day window |
| Orforglipron | No | No new papers in 30-day window (trial activity is high — see Clinical Trials section) |
| Retatrutide | No | No new papers in 30-day window |
| CagriSema | No | No new papers in 30-day window |
| Baricitinib | No | No new papers in 30-day window (but 2 Phase 3 trials now recruiting) |

### Notable Individual Papers

- **"Autologous and allogeneic stem cell-derived islet therapy in three recipients with type 1 diabetes"** — Published in *The Lancet Diabetes & Endocrinology* (2026-Feb-26). [PMID: 41765034](https://pubmed.ncbi.nlm.nih.gov/41765034/). High-impact journal; directly relevant to T1D cure research.

- **"Teplizumab in Stage 2 T1D"** — First real-world clinical practice report on teplizumab feasibility. [PMID: 41796109](https://pubmed.ncbi.nlm.nih.gov/41796109/).

- **"SGLT2 Inhibitor Canagliflozin Promotes β-Cell Regeneration"** — [PMID: 41814144](https://pubmed.ncbi.nlm.nih.gov/41814144/). Cross-cutting finding: an SGLT2 inhibitor showing beta cell regeneration properties. Relevant to both T2D remission and beta cell biology.

- **"Closed-Loop Automated Insulin Delivery in Patients With Type 2 Diabetes: A Meta-Analysis"** — [PMID: 41830110](https://pubmed.ncbi.nlm.nih.gov/41830110/). Evidence level 1a (systematic review of RCTs). Supports expanding closed-loop tech to T2D.

- **"EASD/ADA Position Statement on Individualizing Diabetes Technology"** — [PMID: 41817442](https://pubmed.ncbi.nlm.nih.gov/41817442/). Joint position from EASD and ADA. Evidence level G (guideline).

---

## Gap Analysis Summary

### Top 5 Under-Researched Intersections (Gap Score 100/100)

| Rank | Domain 1 | Domain 2 | Joint Pubs | Expected | Opportunity |
|------|----------|----------|------------|----------|-------------|
| 1 | Beta Cell Regen | Health Equity | 0 | 1,586 | HIGH |
| 2 | Insulin Resistance | Islet Transplant | 1 | 2,099 | HIGH |
| 3 | Islet Transplant | GWAS / Polygenic | 0 | 1,084 | HIGH |
| 4 | Islet Transplant | Personalized Nutrition | 0 | 371 | HIGH |
| 5 | Islet Transplant | Drug Repurposing | 0 | 363 | HIGH |

### Alignment with Tier 1 Contribution Areas

| Gap Finding | Tier 1 Alignment | Action Potential |
|-------------|------------------|------------------|
| Drug Repurposing intersections (gaps #5, #15, #20-23) | **Tier 1: Drug Repurposing Screen** | Run repurposing analysis focusing on islet transplant, closed-loop, CGM, and LADA intersections |
| GWAS/Polygenic + technology gaps (#7, #8) | **Tier 1: Multi-Omics Biomarker Integration** | Explore whether genetic risk profiles could inform technology selection |
| Health Equity gaps (#1, #6, #14, #16, #22, #24) | **Tier 1: Epidemiological Data Analysis** | Multiple domains have zero overlap with health equity — systematic equity analysis opportunity |
| Islet Transplant is the most isolated domain (6 of top 6 gaps) | **Tier 1: Clinical Trial Intelligence** | Map islet transplant trials against adjacent domains for combination opportunities |

---

## Breaking News (Web Search, Last 7 Days)

### Significant Items

1. **ATTD 2026 Conference (Barcelona, March 11-14)** — Dexcom presented new data showing long-term G7 use supports weight management and lowers A1C in non-insulin T2D patients. Dexcom Smart Basal feasibility study showed safety/efficacy for T2D basal insulin optimization. *Evidence level: 2b (conference presentations). Relevance: Diabetes Technology, Health Equity.*

2. **Bold New T1D Cure Approach (March 2)** — MUSC researcher Leonardo Ferreira developing two-part therapy: lab-made insulin-producing cells + custom-engineered protective immune cells. $1M backing from Breakthrough T1D. Goal: restore beta cells without immunosuppression. *Evidence level: 5 (preclinical). Relevance: T1D Stem Cell Cure, Immunotherapy.*

3. **Ozempic Tablets FDA Approved** — Oral semaglutide for T2D approved; availability expected Q2 2026. 25mg supplemental application pending. *Evidence level: G (regulatory action). Relevance: T2D GLP-1 New.*

4. **Medtronic MiniMed 780G Milestones** — Medicare access granted; FDA clearance for ultra rapid-acting insulin use and for insulin-requiring T2D. *Evidence level: G (regulatory action). Relevance: Diabetes Technology, Health Equity.*

5. **ADA Standards of Care 2026 Released** — Updates include CGM recommended at diabetes onset and new guidance on glucose-lowering therapies with CKD. *Evidence level: G (guideline). Relevance: All domains.*

### Pending FDA Decisions (2026)
- **Orforglipron** (Eli Lilly) — Oral GLP-1 for T2D; FDA submission expected 2026
- **CagriSema** (Novo Nordisk) — Semaglutide + cagrilintide combo; working toward FDA approval 2026
- **Retatrutide** (Eli Lilly) — Triple agonist (GLP-1/GIP/glucagon); Phase 3 data showed 28.7% weight loss at 68 weeks

---

## Recommended Actions

### Immediate (This Week)

1. **Review the Lancet stem cell paper** — "Autologous and allogeneic stem cell-derived islet therapy in three recipients with T1D" (PMID 41765034). Published in a top-tier journal. Apply triple-source validation per Research Doctrine and add to Validation Log.

2. **Review the teplizumab real-world paper** — First clinical practice report (PMID 41796109). Valuable for updating the T1D cure landscape. Currently BRONZE evidence (single case series); seek confirming sources.

3. **Review the canagliflozin beta cell regeneration paper** — (PMID 41814144). Cross-cutting SGLT2i + beta cell finding. Check if this connects to drug repurposing analysis (Tier 1 priority).

4. **Add ATTD 2026 findings to tracker** — Dexcom T2D data and Medtronic FDA clearances are noteworthy for Technology and Health Equity tracking.

### Short-Term (This Month)

5. **Begin comparing snapshots on next run** — Today's snapshots are the baseline. On next execution, compare against `clinical_trials_snapshot_2026-03-15.json` and `pubmed_recent_snapshot_2026-03-15.json` for deltas.

6. **Flag the Drug Repurposing publication gap** — Only 3 papers in 30 days but this is a Tier 1 priority area. Our planned Drug Repurposing Screen (Project 4) addresses a genuine literature void. Prioritize this project.

7. **Update Research Tracker** with Vertex VX-880 Phase 3 status (2 trials recruiting), Lilly baricitinib T1D prevention (2 Phase 3 trials now recruiting), and Novo Nordisk CagriSema pipeline status.

8. **Review EASD/ADA joint position statement on diabetes technology** — (PMID 41817442). This is guideline-level evidence that may affect our Technology Accessibility analysis (Tier 2).

### Scripts to Run Next

All scripts are current — no re-runs needed today. Suggested next run schedule:
- `hub_monitor.py` — Daily
- `baseline_clinical_trials.py` — Biweekly (next: 2026-03-29)
- `baseline_pubmed_alerts.py` — Weekly (next: 2026-03-22)
- `project1_literature_gap_analysis.py` — Monthly (next: 2026-04-15)

---

*Generated by Diabetes Research Hub Monitor — 2026-03-15*
*This is an automated review report. No existing files were modified.*
